/ Medical Professionals


Rigorous and groundbreaking science has always been at the core of what we do at Genentech. Our R&D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics.

  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
Managed by Roche
Molecule Indication Phase
Alectinib ALK+ metastatic non-small cell lung cancer
Anti-OX40 MAb Solid tumors
Anti-PDL1 MAb Solid tumors *
Metastatic melanoma *
Anti-STEAP1 Antibody drug conjugate

Prostate Cancer

Antibody drug conjugate Pancreatic and ovarian cancers
Antibody drug conjugate Solid tumors
Bcl-2 Inhibitor (GDC-0199/ABT199)

Chronic lymphocytic leukemia and non-Hodgkin's lymphoma


1st line glioblastoma multiforme


1st line metastatic ovarian cancer


Adjuvant breast cancer, HER2-negative


Adjuvant breast cancer, HER2-positive


Adjuvant non-small cell lung cancer


High-risk carcinoid

ChK1 Inhibitor (GDC-0575)

Solid tumors

Cobimetinib (MEK Inhibitor, GDC-0973) Solid tumors *
Metastatic melanoma *
Duligotuzmab (Anti-HER3/EGFR DAF MAb) Solid tumors with mutant KRAS
ERK Inhibitor (GDC-0994) Solid tumors

1st line metastatic non-small cell lung cancer, EGFR mutation positive

IDO Inhibitor (GDC-0919) Solid tumors
Ipatasertib Solid tumors
Gastric cancer
Triple negative breast cancer
Prostate cancer
Lifastuzumab vedotin Platinum-resistant ovarian cancer
Non-small cell lung cancer and ovarian cancer

Diffuse large B-cell lymphoma


Front-line indolent non-Hodgkin's lymphoma


Refractory indolent Non Hodgkin's lymphoma


Front-line chronic lymphocytic leukemia


metastatic colorectal cancer


metastatic non-small cell lung cancer


Avastin-naïve recurrent glioblastoma


1st line non-squamous non-small cell lung cancer


1st line squamous non-small cell lung cancer


metastatic HER2-negative gastric cancer


triple negative metastatic breast cancer


Early HER2-positive breast cancer


HER2-positive gastric cancer


2nd line HER2-positive metastatic breast cancer

Pictilisib (PI3 Kinase Inhibitor) ER+ metastatic breast cancer *
Metastatic HER2-/HR+ breast cancer *
Metastatic non-small cell lung cancer *
Polatuzumab vedotin (Anti-CD79b ADC) Non-Hodgkin's lymphoma and diffuse large B-cell lymphoma *
SERD (GDC-0810) ER+ HER2-negative breast cancer
SERD (GDC-0927) ER+ HER2-negative breast cancer
Taselisib (PI3 Kinase Inhibitor) HER2-negative metastatic breast cancer *
Solid tumors and HR+ breast cancer *
Trastuzumab emtansine (T–DM1)

1st line HER2-positive metastatic breast cancer


3rd line HER2-positive metastatic breast cancer


Adjuvant metastatic melanoma, BRAF mutation positive


Papillary thyroid cancer, BRAF mutation positive


Metastatic melanoma, BRAF mutation positive


Operable basal cell carcinoma

Etrolizumab Ulcerative colitis *

Severe asthma

New Molecular Entity Inflammatory Diseases
Obinutuzumab Lupus Nephritis
Omalizumab Chronic idiopathic urticaria *
Rituximab Pemphigus Vulgaris
Sodium Hyaluronate


Tocilizumab Early rheumatoid arthritis *
Systemic sclerosis *
Giant Cell Arteritis *
Crenezumab Alzheimer's Disease
Gantenerumab Alzheimer's Disease
Nav1.7 Inhibitor (GDC-0276) Pain

Primary progressive multiple sclerosis


Relapsing multiple sclerosis


Type 2 diabetes

Anti-Influenza A Influenza
Lampalizumab Geographic atrophy associated with advanced age-related macular degeneration *

Sustained delivery age-related macular degeneration/retinal vein occlusion/diabetic macular edema

No molecules match your search.

Accessing Investigational Medicines

Learn how patients gain access to medicines before they are FDA-approved.

Partner with Us

Approximately 50% of our pipeline and marketed products involve some kind of collaboration.